Aliskiren is an orally active, non-peptide, potent and selective direct inhibitor of human renin. By inhibiting the enzyme renin, aliskiren inhibits the RAAS at the point of activation, blocking the conversion of angiotensinogen to angiotensin I and decreasing levels of angiotensin I and angiotensin II.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
Aliskiren is the active ingredient of these drugs:
Austria Canada Cyprus Estonia Hong Kong
South Africa United States
Aliskiren is also found within below combination drugs:
CO RASILEZ , CO TEKTURNA , RASILAMLO , RASILEZ HCT , RASILLES HTC , TEKTURNA HCT